ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Rheumatoid Factor"

  • Abstract Number: 1754 • ACR Convergence 2023

    Novel and Unique Rheumatoid Factors Cross-React with Viral Epitopes in COVID-19

    Maya Amjadi1, Maxwell Parker2, Zihao Zheng1, Alex Robbins1, Michael Denny1, Sara McCoy3, Irene Ong1 and Miriam Shelef1, 1University of Wisconsin, Madison, WI, 2University of Wisconsin-Madison, Madison, WI, 3University of Wisconsin School of Medicine and Public Health, Middleton, WI

    Background/Purpose: Rheumatoid factors (RFs), polyreactive antibodies canonically known to bind two conformational epitopes of IgG, are a hallmark of rheumatoid arthritis but also can arise…
  • Abstract Number: 1772 • ACR Convergence 2023

    Rheumatoid Arthritis-Specific Rheumatoid Factors Develop in Some COVID-19 Patients

    Adam Titi1, Ryan Adyniec2, Nat Murren1 and Miriam Shelef1, 1University of Wisconsin, Madison, WI, 2University of Wisconsin-Madison, Madison, WI

    Background/Purpose: Rheumatoid factors (RFs), antibodies canonically known to bind two conformational epitopes of IgG Fc, are a hallmark of rheumatoid arthritis (RA) but also can…
  • Abstract Number: 1915 • ACR Convergence 2023

    Scleritis and Development of Autoimmune Disease: A Case Series

    Tessalyn Morrison1, Moriah Gottman2, Marcia Friedman3 and Daniela Ghetie4, 1University of Vermont, Burlington, VT, 2Oregon Health & Science University, Milwaukie, OR, 3Alpine Immune Sciences, Inc., Beaverton, OR, 4Oregon Health & Science University, Portland, OR

    Background/Purpose: Scleritis involves inflammation of the sclera caused by trauma, infections, or autoimmune conditions. The purpose of our study was to understand the relationship between…
  • Abstract Number: 2141 • ACR Convergence 2023

    Glucocorticoid Treatment in Early Rheumatoid Arthritis Is Associated with Increased Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Levels: A Post-hoc Analysis of a Randomized Controlled Trial (NORD-STAR)

    Kristina Lend1, Jos W.R. Twisk2, Nupur Kumar3, John Lampa4, Anna Rudin5, Merete Hetland6, Till Uhlig7, Dan Nordstrom8, Mikkel Østergaard9, Marte Schrumpf Heiberg10, Espen A Haavardsholm10, Bjorn Gudbjornsson11, Tuulikki Sokka-Isler12, Gerdur Maria Grondal13, Kim Hørslev-Petersen14, Michael Nurmohamed2, Ronald van Vollenhoven2 and Johan Frostegård3, 1Amsterdam UMC, Karolinska Institute, Stockholm, Sweden, 2Amsterdam University Medical Centers, Amsterdam, Netherlands, 3Karolinska Institutet, Stockholm, Sweden, 4Stockholm County, Hãsselby, Sweden, 5Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 6Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, 7Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, 8Helsinki University Hospital, Helsinki, Finland, 9Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, 10Diakonhjemmet Hospital, Oslo, Norway, 11Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, 12Jyvaskyla Central Hospital, Jyväskylä, Finland, 13Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, 14University of Southern Denmark, Odense, Denmark

    Background/Purpose: Rheumatoid arthritis (RA) is associated with an elevated risk for developing atherosclerotic cardiovascular disease (CVD). Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key…
  • Abstract Number: 2148 • ACR Convergence 2023

    Do High RF Titers Impact Response to TNF Inhibitors? Comparison of Certolizumab Pegol and Adalimumab in Patients with RA and High Titers of RF: A Post Hoc Analysis of a Phase 4 Trial

    Josef S Smolen1, Peter C. Taylor2, Yoshiya Tanaka3, Carlos Cara4, Bernard Lauwerys5, Ricardo Xavier6, Jeffrey R Curtis7, Ted R Mikuls8 and Michael Weinblatt9, 1Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, 2Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 3University of Occupational and Environmental Health, Kitakyushu, Japan, 4UCB Pharma, Madrid, Spain, 5UCB Pharma, Brussels, Belgium, 6Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 7Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, 8Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, 9Division of Rheumatology, Inflammation and Immunity, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: In patients with RA, high RF titers are considered a poor prognostic factor and are associated with higher disease activity, risk of radiographic progression,…
  • Abstract Number: 1989 • ACR Convergence 2022

    Predictors of Flare in the RHEUmatoid Arthritis Medication TAPering (RHEUMTAP) Cohort

    Nada Alrifai1, Mohamed Tageldin2, Malavikalakshmi Attur2, Nicholas Wilson2, Rebecca schorr2 and Tarun Sharma2, 1Allegheny Health Network, Pittsburgh, 2Allegheny Health Network, Pittsburgh, PA

    Background/Purpose: Long term use of conventional synthetic DMARDs (csDMARDs) and biologics in RA has clinical risks including infection and malignancy. Few RCTs and real-world studies…
  • Abstract Number: 2043 • ACR Convergence 2022

    What Does Isolated Anti-Ro52 Antibody Positivity Mean in Sjögren’s Syndrome?

    Eléonore Bettacchioli1, Alain Saraux2, Alice Tison3, Divi CORNEC4, Maryvonne Dueymes1, Marta Alarcon-Riquelme5 and Valerie Devauchelle6, 1Immunology and Immunotherapy Laboratory, CHRU Brest, Brest, France, 2CHU Brest, Brest, France, 3Rheumatology Department, CHRU Brest, Brest, France, 4CHRU Brest, Brest, France, 5Center for Genomics and Oncological Research (GENYO), Granada, Spain, 6Université de Bretagne Occidentale, Brest, France

    Background/Purpose: Primary Sjögren's syndrome (pSS) is a systemic autoimmune disease characterized by a triad of dryness, pain and fatigue in affected patients. Its diagnosis is…
  • Abstract Number: 2249 • ACR Convergence 2022

    Impact of Interstitial Lung Disease on COVID-19 Severity Among Patients with Rheumatoid Arthritis: A Multicenter Comparative Study

    Gabriel Figueroa Parra1, Emily Gilbert2, Maria Valenzuela Almada1, Sebastian Vallejo1, Matthew Neville3, Naomi Patel4, Claire Cook5, Xiaoqing Fu5, Ramla Hagi5, Gregory McDermott6, Michael Dilorio6, Lucy Masto6, Kathleen Vanni6, Emily Kowalski6, Grace Qian6, Zachary Wallace5, Ali Duarte-Garcia1 and Jeffrey Sparks7, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Jacksonville, FL, 3Mayo Clinic, Phoenix, AZ, 4Massachusetts General Hospital, Sale Creek, TN, 5Massachusetts General Hospital, Boston, MA, 6Brigham and Women's Hospital, Boston, MA, 7Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Rheumatoid arthritis (RA) has been associated with severe COVID-19, but few studies have investigated outcomes in RA phenotypes such as interstitial lung disease (RA-ILD),…
  • Abstract Number: 0080 • ACR Convergence 2022

    Utilization of Biologic and Targeted Disease Modifying Antirheumatic Therapy in Patients with Rheumatoid Arthritis and Breast Cancer

    Juan Ruiz1, Chi-Fang Wu2, Hui Zhao2, Sharon Giordano2, Suja Rajan3 and Maria Suarez-Almazor4, 1The University of Texas MD Anderson Cancer Center, Houston, TX, 2The University of Texas, MD Anderson Cancer Center, Houston, TX, 3University of Texas School of Public Health, Houston, TX, 4MD Anderson Cancer Center, Houston, TX

    Background/Purpose: Biologic and targeted synthetic disease modifying antirheumatic drugs (bDMARD and tsDMARD) are immunosuppressant, and there have been concerns that they might impact tumor immunity…
  • Abstract Number: 0533 • ACR Convergence 2022

    Sputum RA-Associated Autoantibodies Independently Associate with Future Development of Classified RA in an At-Risk Cohort of Individuals with Systemic Anti-CCP Positivity

    Timothy Wilson1, Jacob Welch2, Marie Feser2, Elizabeth Bemis2, Claudia Lugo2, Gary S. Firestein3, Thomas F. Bumol4, Jill Norris5, V. Michael Holers6, Kevin D Deane7 and Kristen Demoruelle2, 1University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 2University of Colorado Anschutz Medical Campus, Aurora, CO, 3University of California, San Diego, San Diego, CA, 4Allen Institute for Immunology, Seattle, WA, 5Colorado School of Public Health, Aurora, CO, 6University of Colorado, Denver, CO, 7University of Colorado Denver Anschutz Medical Campus, Denver, CO

    Background/Purpose: Presence of systemic anti-CCP-IgG antibodies in individuals without inflammatory arthritis (IA) strongly predicts developing future classified RA. However, published data also demonstrate that 50-70%…
  • Abstract Number: 0714 • ACR Convergence 2022

    Real-World Treatment Effectiveness of Disease-Modifying Anti-Rheumatic Drugs by Serostatus Among Patients with Rheumatoid Arthritis

    Yinzhu Jin, Jun Liu, Rishi Desai and Seoyoung Kim, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Serostatus may be associated with different responses to treatment with biologic disease-modifying anti-rheumatic drugs (DMARD) or Janus kinase inhibitors (JAKi) in patients with rheumatoid…
  • Abstract Number: 0883 • ACR Convergence 2022

    Serum Cholesterol Loading Capacity on Macrophages Is Dependent on Oxidized Low-density Lipoprotein and Regulated by Seropositivity and C-reactive Protein in Patients with Rheumatoid Arthritis

    George A Karpouzas1, Bianca Papotti2, Sarah Ormseth3, Marcella Palumbo2, elizabeth Hernandez3, Maria Pia Adorni2, Francesca Zimetti2, Matthew Budoff4 and Nicoletta Ronda5, 1Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, 2University of Parma, Parma, Italy, 3The Lundquist Institute, Torrance, CA, 4Harbor-UCLA Medical Center and the Lundquist Institute, Torrance, CA, 5University of Parma, Parma

    Background/Purpose: Excessive cholesterol accumulation in macrophages underlies foam cell formation, initiation and progression of atherosclerosis. Low-density lipoprotein (LDL) oxidation and unregulated uptake by macrophages are…
  • Abstract Number: 0891 • ACR Convergence 2022

    Rheumatoid Arthritis and the Rheumatic Disease Comorbidity Index (RDCI): Its Impact on Disease Activity

    Sultana Abdulaziz1, Suzan Attar2, Renad Ahmed2, Hamza Fida2, Omar Bokhary2, Anas Alyazidi2 and Abdulelah Abumohssin2, 1King Fahad Hospital, Jeddah, Saudi Arabia, 2King Abdulaziz University, Jeddah, Saudi Arabia

    Background/Purpose: Comorbid conditions in the setting of rheumatoid arthritis (RA) play an important role in predicting disease activity and functional impairment (1). Application of a…
  • Abstract Number: 0906 • ACR Convergence 2022

    Patients with Seronegative Rheumatoid Arthritis Have a Different Ultrasound-assessed Joint Disease Phenotype Than Seropositive Patients

    Natalia Carbonell-Bobadilla1, Carina Soto-Fajardo2, Luis M Amezcua-Guerra3, Ana Beatriz Batres Marroquin4, Ana Cristina Medina5, Tania Vargas3, Adrián Hernández-Diazcouder3, Valentín Jiménez-Rojas3, Carlos Pineda5 and Luis H Silveira6, 1National Institute of Cardiology Ignacio Chávez, Ciudad de México, Mexico, 2Instituto Nacional de Rehabilitacion "Luis Guillermo Ibarra Ibarra", Ciudad de México, Mexico, 3Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, Mexico, 4Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Ciudad de México, Mexico, 5Instituto Nacional de Rehabilitacion, Ciudad de México, Mexico, 6Instituto Nacional de Cardiología, Ciudad de México, Mexico

    Background/Purpose: Seronegative rheumatoid arthritis (SNRA) tends to be less severe in its presentation and evolution than seropositive rheumatoid arthritis(SPRA), but controversy exists because there have…
  • Abstract Number: 0910 • ACR Convergence 2022

    Rheumatoid Arthritis Associated Interstitial Lung Disease: The Role of Non-Criteria Autoantibodies

    Albert Pérez-Isidro1, Raul Castellanos-Moreira1, Juan Camilo Sarmiento-Monroy2, Noemi de Moner1, Maresa Grundhuber3, Odette Vinas1, Raimon Sanmarti2 and Estibaliz Ruiz-Ortiz1, 1Hospital Clinic of Barcelona, Barcelona, Spain, 2Hospital Clínic de Barcelona, Barcelona, Spain, 3Thermo Fisher Scientific, Freiburg, Germany

    Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic joint inflammation. RA-associated interstitial lung disease (ILD) is the most frequent and severe extra-articular…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 11
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology